IPSEN PHARMA

In News

Ipsen gets the Memo, penning €700M deal to buy rare disease biotech for clinical-stage asset - Fierce Biotech

Fierce Biotech - Jul 01, 2026

Ipsen Weighs U.S. Manufacturing Investment - WSJ

WSJ - Sep 11, 2026

Ipsen - September 2026 - Monthly information relative to the total number of voting rights and shares composing the share capital - Yahoo Finance

Yahoo Finance - Oct 07, 2026

Another setback for Ipsen's Albireo portfolio as Bylvay flunks phase 3 trial - Fierce Pharma

Fierce Pharma - Jul 24, 2026

Characterizing the patient experience: The role of patient‑reported outcomes - Ipsen

Ipsen - Oct 12, 2026

IPSEN - Buy-back programme - Art 5 of MAR - Week 39 - 2026 - GlobeNewswire

GlobeNewswire - Sep 28, 2026

Ipsen to buy Swiss biotech Memo Therapeutics in potential $800M deal - BioPharma Dive

BioPharma Dive - Jul 01, 2026

Pharma M&A Roundup: Ipsen to Acquire Kartos Therapeutics, Zymeworks to Acquire Theravance Biopharma - Pharmaceutical Executive

Pharmaceutical Executive - Jun 29, 2026

Ipsen set to rival Botox after duo of Phase III migraine wins - Pharmaceutical Technology

Pharmaceutical Technology - Jul 10, 2026

Drugmaker Ipsen Sees More Deals Coming to Continue Buying Spree - WSJ

WSJ - Jul 03, 2026

Ipsen’s Botox rival Dysport charts new horizons with dual phase 3 wins in migraine - Fierce Pharma

Fierce Pharma - Jul 09, 2026

Ipsen pens $1.7B deal to acquire Kartos for potential Jakafi add-on therapy for myelofibrosis - Fierce Biotech

Fierce Biotech - Jun 29, 2026

Stay Informed

Join our mailing list for the latest report releases and upcoming event notifications.

Headquartered in Boston, Mass., for over 50 years, BCC Research takes pride in being your trusted custom research and data analysts. Our mission is to provide businesses with reputable data and market research reports, so that they gain new perspectives into their field and better understand their target audience. We enable companies to access reliable information, accurate forecasts, and actionable insights, so that they may become leaders in their industry.

AI Sentiment